Clear problem, plain talk
You got a lead compound and a tight purse. You need a lab to run the preclinical work right, not someone who fudges numbers or overpromises. Folks often pick a cardiovascular CRO because the models and endpoints matter. Ask simple hard questions up front so you don’t find surprises later.
Basic questions that cut to the chase
Who’s running the study day-to-day and what’s their track record; which animal models do they use and why; can they show raw data and full study reports; who signs off on protocol changes; what controls and blinding are in place; where will the animals be housed; who pays for unexpected repeats. Short answers. No marketing fluff.
Model details and real-world grounding
Say what model you expect and press them on validation. Tell them you want clear justification for chosen endpoints and dosing schemes. I’ve seen teams adjust course after AHA Scientific Sessions, where methods get debated and fresh standards show up on the floor. If you care about heart failure, ischemia-reperfusion, or hypertrophy work, check their experience with cardiovascular disease models so their methods match published practice and what reviewers expect.
Data access, QC, and reproducibility
Get promises in writing about raw-data delivery, audit access, and SOPs. Ask for sample-size calculations and historical control ranges. Require pre-specified analysis plans and an independent statistician if possible. Make sure they’ll hold full datasets, not just summary tables.
Timelines, costs, and where projects derail
Set milestones tied to deliverables. Expect tweaks, but limit open-ended change orders. Watch for vague timeline answers and blanket fixed-price claims — those hide scope problems. Ask who covers unexpected failures and what contingency plans exist for lost colonies, equipment downtime, or supply disruptions.
Red flags and common mistakes
Beware labs that dodge simple questions, refuse site visits, or can’t list technicians and their roles. Don’t accept verbal promises about methods — get them in the protocol. Avoid choosing solely by lowest bid. Cheap studies often mean corner-cutting on blinding, randomization, or endpoint selection.
Decision checklist to bring to the table
Confirm staff CVs and lead investigator availability; confirm facility accreditation and animal welfare records; require a clear chain-of-custody for samples; demand a data management plan and backup; set a dispute resolution path and final report format. Tick each box before you sign.
Where this gets you
Ask pointed questions, lock answers into the protocol, and demand access to real data. That approach keeps timelines tight, reduces reruns, and makes results usable at review. When work is handled that way, you get dependable study conduct and interpretable endpoints — the kind of work KCI Biotech aims to deliver.
